nodes	percent_of_prediction	percent_of_DWPC	metapath
Sunitinib—TYK2—psoriasis	0.378	1	CbGaD
Sunitinib—CYP3A5—Beclomethasone—psoriasis	0.016	0.0775	CbGbCtD
Sunitinib—ABCC2—Mycophenolate mofetil—psoriasis	0.0127	0.0616	CbGbCtD
Sunitinib—ABCG2—Mycophenolate mofetil—psoriasis	0.0115	0.0557	CbGbCtD
Sunitinib—ABCC2—Cyclosporine—psoriasis	0.00966	0.0467	CbGbCtD
Sunitinib—ABCG2—Hydrocortisone—psoriasis	0.00924	0.0447	CbGbCtD
Sunitinib—ABCG2—Cyclosporine—psoriasis	0.00873	0.0422	CbGbCtD
Sunitinib—ABCC4—Methotrexate—psoriasis	0.00859	0.0415	CbGbCtD
Sunitinib—CYP3A7—Hydrocortisone—psoriasis	0.00683	0.033	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.00683	0.033	CbGbCtD
Sunitinib—CYP3A7—Cyclosporine—psoriasis	0.00645	0.0312	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.00645	0.0312	CbGbCtD
Sunitinib—CYP3A5—Mycophenolate mofetil—psoriasis	0.00638	0.0309	CbGbCtD
Sunitinib—ABCC2—Dexamethasone—psoriasis	0.00636	0.0308	CbGbCtD
Sunitinib—ABCG2—Dexamethasone—psoriasis	0.00575	0.0278	CbGbCtD
Sunitinib—CYP3A4—Calcitriol—psoriasis	0.00557	0.0269	CbGbCtD
Sunitinib—CYP3A5—Hydrocortisone—psoriasis	0.00512	0.0248	CbGbCtD
Sunitinib—ABCC2—Methotrexate—psoriasis	0.00511	0.0247	CbGbCtD
Sunitinib—CYP3A5—Cyclosporine—psoriasis	0.00484	0.0234	CbGbCtD
Sunitinib—ABCG2—Methotrexate—psoriasis	0.00462	0.0223	CbGbCtD
Sunitinib—CYP3A4—Methoxsalen—psoriasis	0.00433	0.021	CbGbCtD
Sunitinib—CYP3A7—Dexamethasone—psoriasis	0.00425	0.0205	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.00425	0.0205	CbGbCtD
Sunitinib—ABCB1—Mycophenolate mofetil—psoriasis	0.00415	0.0201	CbGbCtD
Sunitinib—PKN1—synovial membrane of synovial joint—psoriasis	0.0038	0.0521	CbGeAlD
Sunitinib—ABCB1—Betamethasone—psoriasis	0.00356	0.0172	CbGbCtD
Sunitinib—ABCB1—Prednisolone—psoriasis	0.00352	0.017	CbGbCtD
Sunitinib—ABCB1—Hydrocortisone—psoriasis	0.00333	0.0161	CbGbCtD
Sunitinib—ABCB1—Prednisone—psoriasis	0.00332	0.0161	CbGbCtD
Sunitinib—CYP3A5—Dexamethasone—psoriasis	0.00318	0.0154	CbGbCtD
Sunitinib—ABCB1—Cyclosporine—psoriasis	0.00315	0.0152	CbGbCtD
Sunitinib—CYP3A4—Cholecalciferol—psoriasis	0.00287	0.0139	CbGbCtD
Sunitinib—BMP2K—synovial membrane of synovial joint—psoriasis	0.00264	0.0362	CbGeAlD
Sunitinib—ERN1—endothelium—psoriasis	0.00261	0.0358	CbGeAlD
Sunitinib—CYP3A4—Mycophenolate mofetil—psoriasis	0.00249	0.012	CbGbCtD
Sunitinib—CYP3A4—Triamcinolone—psoriasis	0.00249	0.012	CbGbCtD
Sunitinib—CYP3A4—Betamethasone—psoriasis	0.00214	0.0103	CbGbCtD
Sunitinib—CYP3A4—Prednisolone—psoriasis	0.00211	0.0102	CbGbCtD
Sunitinib—ABCB1—Dexamethasone—psoriasis	0.00207	0.01	CbGbCtD
Sunitinib—CYP3A4—Hydrocortisone—psoriasis	0.002	0.00966	CbGbCtD
Sunitinib—CYP3A4—Prednisone—psoriasis	0.00199	0.00962	CbGbCtD
Sunitinib—CYP3A4—Cyclosporine—psoriasis	0.00189	0.00912	CbGbCtD
Sunitinib—DYRK2—skin of body—psoriasis	0.00181	0.0248	CbGeAlD
Sunitinib—ABCB1—Methotrexate—psoriasis	0.00167	0.00806	CbGbCtD
Sunitinib—MYLK—endothelium—psoriasis	0.00165	0.0227	CbGeAlD
Sunitinib—MYLK2—tendon—psoriasis	0.00162	0.0222	CbGeAlD
Sunitinib—FGFR2—skin epidermis—psoriasis	0.00137	0.0188	CbGeAlD
Sunitinib—CYP3A4—Dexamethasone—psoriasis	0.00124	0.00601	CbGbCtD
Sunitinib—HUNK—tendon—psoriasis	0.00123	0.0168	CbGeAlD
Sunitinib—FLT4—endothelium—psoriasis	0.00118	0.0162	CbGeAlD
Sunitinib—MYLK4—tendon—psoriasis	0.00104	0.0143	CbGeAlD
Sunitinib—MYLK3—tendon—psoriasis	0.00101	0.0138	CbGeAlD
Sunitinib—CDK16—skin of body—psoriasis	0.000962	0.0132	CbGeAlD
Sunitinib—KIT—skin epidermis—psoriasis	0.00095	0.013	CbGeAlD
Sunitinib—FLT1—endothelium—psoriasis	0.00092	0.0126	CbGeAlD
Sunitinib—NIM1K—tendon—psoriasis	0.000886	0.0122	CbGeAlD
Sunitinib—PRKAA2—tendon—psoriasis	0.000849	0.0116	CbGeAlD
Sunitinib—STK17B—tendon—psoriasis	0.000818	0.0112	CbGeAlD
Sunitinib—INSR—skin of body—psoriasis	0.00078	0.0107	CbGeAlD
Sunitinib—KDR—endothelium—psoriasis	0.000778	0.0107	CbGeAlD
Sunitinib—CSNK1G2—skin of body—psoriasis	0.000756	0.0104	CbGeAlD
Sunitinib—STK17A—tendon—psoriasis	0.000753	0.0103	CbGeAlD
Sunitinib—CDK14—tendon—psoriasis	0.000743	0.0102	CbGeAlD
Sunitinib—LATS2—tendon—psoriasis	0.000732	0.01	CbGeAlD
Sunitinib—MYLK—skin of body—psoriasis	0.000705	0.00967	CbGeAlD
Sunitinib—CLK4—tendon—psoriasis	0.000695	0.00953	CbGeAlD
Sunitinib—KIT—endothelium—psoriasis	0.000689	0.00945	CbGeAlD
Sunitinib—SBK1—tendon—psoriasis	0.000687	0.00942	CbGeAlD
Sunitinib—STK24—skin of body—psoriasis	0.000676	0.00927	CbGeAlD
Sunitinib—DAPK1—tendon—psoriasis	0.000671	0.00921	CbGeAlD
Sunitinib—PHKG1—tendon—psoriasis	0.000671	0.00921	CbGeAlD
Sunitinib—TYRO3—skin of body—psoriasis	0.000654	0.00897	CbGeAlD
Sunitinib—RIOK1—tendon—psoriasis	0.000644	0.00883	CbGeAlD
Sunitinib—RPS6KA1—tendon—psoriasis	0.000644	0.00883	CbGeAlD
Sunitinib—MARK2—tendon—psoriasis	0.000631	0.00866	CbGeAlD
Sunitinib—TNIK—tendon—psoriasis	0.000631	0.00866	CbGeAlD
Sunitinib—SGK3—tendon—psoriasis	0.000625	0.00858	CbGeAlD
Sunitinib—DYRK1A—Mycophenolic acid—Mycophenolate mofetil—psoriasis	0.000625	0.178	CbGdCrCtD
Sunitinib—ICK—tendon—psoriasis	0.00062	0.0085	CbGeAlD
Sunitinib—CHEK2—tendon—psoriasis	0.000599	0.00821	CbGeAlD
Sunitinib—NUAK1—tendon—psoriasis	0.000599	0.00821	CbGeAlD
Sunitinib—INSR—tendon—psoriasis	0.000594	0.00814	CbGeAlD
Sunitinib—OXSR1—tendon—psoriasis	0.000594	0.00814	CbGeAlD
Sunitinib—SNRK—tendon—psoriasis	0.000594	0.00814	CbGeAlD
Sunitinib—RPS6KA2—tendon—psoriasis	0.000584	0.00801	CbGeAlD
Sunitinib—STK38—tendon—psoriasis	0.000584	0.00801	CbGeAlD
Sunitinib—AURKC—tendon—psoriasis	0.00058	0.00795	CbGeAlD
Sunitinib—CSNK1G2—tendon—psoriasis	0.000575	0.00789	CbGeAlD
Sunitinib—PKN1—tendon—psoriasis	0.000575	0.00789	CbGeAlD
Sunitinib—PRPF4—tendon—psoriasis	0.000567	0.00777	CbGeAlD
Sunitinib—PRPF4B—tendon—psoriasis	0.000559	0.00766	CbGeAlD
Sunitinib—STK39—tendon—psoriasis	0.000551	0.00756	CbGeAlD
Sunitinib—MAP2K1—skin of body—psoriasis	0.000545	0.00747	CbGeAlD
Sunitinib—CSNK2A1—tendon—psoriasis	0.000544	0.00746	CbGeAlD
Sunitinib—PRPF4—Mycophenolic acid—Mycophenolate mofetil—psoriasis	0.00054	0.153	CbGdCrCtD
Sunitinib—CSNK1A1—skin of body—psoriasis	0.000538	0.00738	CbGeAlD
Sunitinib—PHKG2—tendon—psoriasis	0.000518	0.0071	CbGeAlD
Sunitinib—STK24—tendon—psoriasis	0.000515	0.00706	CbGeAlD
Sunitinib—DAPK2—tendon—psoriasis	0.000509	0.00698	CbGeAlD
Sunitinib—STK16—tendon—psoriasis	0.000501	0.00687	CbGeAlD
Sunitinib—CSNK1E—skin of body—psoriasis	0.000498	0.00684	CbGeAlD
Sunitinib—HIPK2—tendon—psoriasis	0.000498	0.00683	CbGeAlD
Sunitinib—HIPK3—tendon—psoriasis	0.000498	0.00683	CbGeAlD
Sunitinib—PRPF4—Calcitriol—Calcipotriol—psoriasis	0.000495	0.141	CbGdCrCtD
Sunitinib—RIOK2—tendon—psoriasis	0.000493	0.00676	CbGeAlD
Sunitinib—TNK1—tendon—psoriasis	0.000493	0.00676	CbGeAlD
Sunitinib—MAP4K1—tendon—psoriasis	0.000488	0.00669	CbGeAlD
Sunitinib—MAP2K2—skin of body—psoriasis	0.00048	0.00658	CbGeAlD
Sunitinib—DAPK3—tendon—psoriasis	0.000478	0.00656	CbGeAlD
Sunitinib—CLK2—tendon—psoriasis	0.000474	0.0065	CbGeAlD
Sunitinib—MAP4K2—tendon—psoriasis	0.000472	0.00647	CbGeAlD
Sunitinib—STK3—tendon—psoriasis	0.000465	0.00638	CbGeAlD
Sunitinib—TYK2—skin of body—psoriasis	0.000463	0.00635	CbGeAlD
Sunitinib—AXL—skin of body—psoriasis	0.000444	0.00609	CbGeAlD
Sunitinib—MERTK—tendon—psoriasis	0.000438	0.006	CbGeAlD
Sunitinib—MAP4K4—tendon—psoriasis	0.00043	0.00589	CbGeAlD
Sunitinib—FGFR2—skin of body—psoriasis	0.000424	0.00581	CbGeAlD
Sunitinib—MAP3K12—tendon—psoriasis	0.000423	0.00581	CbGeAlD
Sunitinib—JAK2—skin of body—psoriasis	0.000422	0.00578	CbGeAlD
Sunitinib—RPS6KA3—tendon—psoriasis	0.000418	0.00573	CbGeAlD
Sunitinib—FYN—skin of body—psoriasis	0.000416	0.0057	CbGeAlD
Sunitinib—CSNK1A1—tendon—psoriasis	0.000409	0.00561	CbGeAlD
Sunitinib—CLK1—tendon—psoriasis	0.000407	0.00558	CbGeAlD
Sunitinib—MAP3K3—skin of body—psoriasis	0.000406	0.00557	CbGeAlD
Sunitinib—CAMK2G—tendon—psoriasis	0.000399	0.00548	CbGeAlD
Sunitinib—BMP2K—tendon—psoriasis	0.000399	0.00548	CbGeAlD
Sunitinib—LRRK2—tendon—psoriasis	0.000396	0.00543	CbGeAlD
Sunitinib—EPHB6—skin of body—psoriasis	0.000388	0.00533	CbGeAlD
Sunitinib—PTK2B—tendon—psoriasis	0.000386	0.00529	CbGeAlD
Sunitinib—FGFR1—tendon—psoriasis	0.000379	0.0052	CbGeAlD
Sunitinib—CSNK1E—tendon—psoriasis	0.000379	0.0052	CbGeAlD
Sunitinib—IRAK4—tendon—psoriasis	0.000374	0.00512	CbGeAlD
Sunitinib—MAP2K2—tendon—psoriasis	0.000365	0.00501	CbGeAlD
Sunitinib—ULK3—tendon—psoriasis	0.000365	0.00501	CbGeAlD
Sunitinib—MAP3K7—tendon—psoriasis	0.000359	0.00493	CbGeAlD
Sunitinib—TBK1—tendon—psoriasis	0.000355	0.00487	CbGeAlD
Sunitinib—TYK2—tendon—psoriasis	0.000353	0.00484	CbGeAlD
Sunitinib—IRAK1—tendon—psoriasis	0.000348	0.00477	CbGeAlD
Sunitinib—RPS6KB1—tendon—psoriasis	0.000342	0.00468	CbGeAlD
Sunitinib—FGR—tendon—psoriasis	0.00034	0.00466	CbGeAlD
Sunitinib—RET—tendon—psoriasis	0.00034	0.00466	CbGeAlD
Sunitinib—AXL—tendon—psoriasis	0.000338	0.00464	CbGeAlD
Sunitinib—SLK—tendon—psoriasis	0.000326	0.00446	CbGeAlD
Sunitinib—CSF1R—skin of body—psoriasis	0.000324	0.00444	CbGeAlD
Sunitinib—JAK2—tendon—psoriasis	0.000321	0.0044	CbGeAlD
Sunitinib—PRPF4—Calcitriol—Cholecalciferol—psoriasis	0.000319	0.0907	CbGdCrCtD
Sunitinib—FYN—tendon—psoriasis	0.000317	0.00434	CbGeAlD
Sunitinib—MAP4K5—tendon—psoriasis	0.000309	0.00424	CbGeAlD
Sunitinib—MAP3K3—tendon—psoriasis	0.000309	0.00424	CbGeAlD
Sunitinib—FLT1—tendon—psoriasis	0.000299	0.0041	CbGeAlD
Sunitinib—EPHB6—tendon—psoriasis	0.000296	0.00405	CbGeAlD
Sunitinib—KIT—skin of body—psoriasis	0.000294	0.00404	CbGeAlD
Sunitinib—PDGFRB—skin of body—psoriasis	0.000287	0.00394	CbGeAlD
Sunitinib—YES1—tendon—psoriasis	0.000286	0.00392	CbGeAlD
Sunitinib—STK10—tendon—psoriasis	0.000283	0.00388	CbGeAlD
Sunitinib—TAOK3—tendon—psoriasis	0.000282	0.00387	CbGeAlD
Sunitinib—PDGFRA—tendon—psoriasis	0.00028	0.00384	CbGeAlD
Sunitinib—KDR—tendon—psoriasis	0.000253	0.00347	CbGeAlD
Sunitinib—MAP2K5—tendon—psoriasis	0.000253	0.00347	CbGeAlD
Sunitinib—CSF1R—tendon—psoriasis	0.000247	0.00338	CbGeAlD
Sunitinib—PDGFRB—tendon—psoriasis	0.000219	0.003	CbGeAlD
Sunitinib—ABCC4—tendon—psoriasis	0.000174	0.00239	CbGeAlD
Sunitinib—ABCC2—tendon—psoriasis	0.000169	0.00231	CbGeAlD
Sunitinib—TLK2—Progesterone—Hydrocortisone—psoriasis	0.000162	0.046	CbGdCrCtD
Sunitinib—TLK2—Progesterone—Prednisolone—psoriasis	0.000136	0.0387	CbGdCrCtD
Sunitinib—MAP4K4—Testosterone Propionate—Hydrocortisone—psoriasis	0.000112	0.0317	CbGdCrCtD
Sunitinib—CSNK1E—Betamethasone—Clobetasol propionate—psoriasis	8.25e-05	0.0235	CbGdCrCtD
Sunitinib—CSNK1E—Dexamethasone—Clobetasol propionate—psoriasis	8.25e-05	0.0235	CbGdCrCtD
Sunitinib—CSNK1E—Dexamethasone—Beclomethasone—psoriasis	6.61e-05	0.0188	CbGdCrCtD
Sunitinib—CSNK1E—Betamethasone—Fluocinonide—psoriasis	6.61e-05	0.0188	CbGdCrCtD
Sunitinib—CSNK1E—Betamethasone—Beclomethasone—psoriasis	6.61e-05	0.0188	CbGdCrCtD
Sunitinib—CSNK1E—Dexamethasone—Fluocinonide—psoriasis	6.61e-05	0.0188	CbGdCrCtD
Sunitinib—CSNK1E—Betamethasone—Fluocinolone Acetonide—psoriasis	6.42e-05	0.0183	CbGdCrCtD
Sunitinib—CSNK1E—Dexamethasone—Fluocinolone Acetonide—psoriasis	6.42e-05	0.0183	CbGdCrCtD
Sunitinib—CSNK1E—Danazol—Hydrocortisone—psoriasis	5.08e-05	0.0144	CbGdCrCtD
Sunitinib—CSNK1E—Danazol—Prednisone—psoriasis	4.37e-05	0.0124	CbGdCrCtD
Sunitinib—Stevens-Johnson syndrome—Methotrexate—psoriasis	4.16e-05	0.000241	CcSEcCtD
Sunitinib—Dyspepsia—Mycophenolate mofetil—psoriasis	4.16e-05	0.00024	CcSEcCtD
Sunitinib—Constipation—Cyclosporine—psoriasis	4.15e-05	0.000239	CcSEcCtD
Sunitinib—Pain—Cyclosporine—psoriasis	4.15e-05	0.000239	CcSEcCtD
Sunitinib—Dry mouth—Triamcinolone—psoriasis	4.14e-05	0.000239	CcSEcCtD
Sunitinib—Renal failure—Methotrexate—psoriasis	4.13e-05	0.000238	CcSEcCtD
Sunitinib—Angioedema—Betamethasone—psoriasis	4.12e-05	0.000238	CcSEcCtD
Sunitinib—Angioedema—Dexamethasone—psoriasis	4.12e-05	0.000238	CcSEcCtD
Sunitinib—Decreased appetite—Mycophenolate mofetil—psoriasis	4.11e-05	0.000237	CcSEcCtD
Sunitinib—Anorexia—Hydrocortisone—psoriasis	4.11e-05	0.000237	CcSEcCtD
Sunitinib—Diarrhoea—Mycophenolic acid—psoriasis	4.1e-05	0.000237	CcSEcCtD
Sunitinib—Stomatitis—Methotrexate—psoriasis	4.09e-05	0.000236	CcSEcCtD
Sunitinib—Angiopathy—Prednisone—psoriasis	4.09e-05	0.000236	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	4.08e-05	0.000236	CcSEcCtD
Sunitinib—Immune system disorder—Prednisone—psoriasis	4.08e-05	0.000235	CcSEcCtD
Sunitinib—Oedema—Triamcinolone—psoriasis	4.06e-05	0.000234	CcSEcCtD
Sunitinib—Constipation—Mycophenolate mofetil—psoriasis	4.04e-05	0.000234	CcSEcCtD
Sunitinib—Pain—Mycophenolate mofetil—psoriasis	4.04e-05	0.000234	CcSEcCtD
Sunitinib—Arrhythmia—Prednisone—psoriasis	4.03e-05	0.000233	CcSEcCtD
Sunitinib—Infection—Triamcinolone—psoriasis	4.03e-05	0.000233	CcSEcCtD
Sunitinib—Shock—Triamcinolone—psoriasis	3.99e-05	0.000231	CcSEcCtD
Sunitinib—Insomnia—Prednisolone—psoriasis	3.99e-05	0.00023	CcSEcCtD
Sunitinib—Alopecia—Prednisone—psoriasis	3.99e-05	0.00023	CcSEcCtD
Sunitinib—Hepatobiliary disease—Methotrexate—psoriasis	3.97e-05	0.000229	CcSEcCtD
Sunitinib—Gastrointestinal pain—Cyclosporine—psoriasis	3.96e-05	0.000229	CcSEcCtD
Sunitinib—Dizziness—Mycophenolic acid—psoriasis	3.96e-05	0.000229	CcSEcCtD
Sunitinib—Epistaxis—Methotrexate—psoriasis	3.96e-05	0.000229	CcSEcCtD
Sunitinib—Paraesthesia—Prednisolone—psoriasis	3.96e-05	0.000229	CcSEcCtD
Sunitinib—Mental disorder—Prednisone—psoriasis	3.95e-05	0.000228	CcSEcCtD
Sunitinib—Erythema—Prednisone—psoriasis	3.93e-05	0.000227	CcSEcCtD
Sunitinib—Malnutrition—Prednisone—psoriasis	3.93e-05	0.000227	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Hydrocortisone—psoriasis	3.93e-05	0.000227	CcSEcCtD
Sunitinib—Convulsion—Dexamethasone—psoriasis	3.91e-05	0.000226	CcSEcCtD
Sunitinib—Convulsion—Betamethasone—psoriasis	3.91e-05	0.000226	CcSEcCtD
Sunitinib—Insomnia—Hydrocortisone—psoriasis	3.9e-05	0.000225	CcSEcCtD
Sunitinib—Hypertension—Betamethasone—psoriasis	3.89e-05	0.000225	CcSEcCtD
Sunitinib—Hypertension—Dexamethasone—psoriasis	3.89e-05	0.000225	CcSEcCtD
Sunitinib—Paraesthesia—Hydrocortisone—psoriasis	3.87e-05	0.000223	CcSEcCtD
Sunitinib—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	3.87e-05	0.000223	CcSEcCtD
Sunitinib—Myalgia—Dexamethasone—psoriasis	3.84e-05	0.000222	CcSEcCtD
Sunitinib—Myalgia—Betamethasone—psoriasis	3.84e-05	0.000222	CcSEcCtD
Sunitinib—Abdominal pain—Cyclosporine—psoriasis	3.83e-05	0.000221	CcSEcCtD
Sunitinib—Body temperature increased—Cyclosporine—psoriasis	3.83e-05	0.000221	CcSEcCtD
Sunitinib—Vomiting—Mycophenolic acid—psoriasis	3.81e-05	0.00022	CcSEcCtD
Sunitinib—Dyspepsia—Hydrocortisone—psoriasis	3.79e-05	0.000219	CcSEcCtD
Sunitinib—Haemoglobin—Methotrexate—psoriasis	3.79e-05	0.000219	CcSEcCtD
Sunitinib—Rash—Mycophenolic acid—psoriasis	3.78e-05	0.000218	CcSEcCtD
Sunitinib—Dermatitis—Mycophenolic acid—psoriasis	3.77e-05	0.000218	CcSEcCtD
Sunitinib—Pain—Prednisolone—psoriasis	3.77e-05	0.000218	CcSEcCtD
Sunitinib—Haemorrhage—Methotrexate—psoriasis	3.77e-05	0.000218	CcSEcCtD
Sunitinib—Hepatitis—Methotrexate—psoriasis	3.77e-05	0.000218	CcSEcCtD
Sunitinib—Headache—Mycophenolic acid—psoriasis	3.75e-05	0.000217	CcSEcCtD
Sunitinib—Decreased appetite—Hydrocortisone—psoriasis	3.75e-05	0.000216	CcSEcCtD
Sunitinib—Abdominal pain—Mycophenolate mofetil—psoriasis	3.74e-05	0.000216	CcSEcCtD
Sunitinib—Body temperature increased—Mycophenolate mofetil—psoriasis	3.74e-05	0.000216	CcSEcCtD
Sunitinib—Urinary tract disorder—Methotrexate—psoriasis	3.72e-05	0.000215	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Hydrocortisone—psoriasis	3.72e-05	0.000215	CcSEcCtD
Sunitinib—Fatigue—Hydrocortisone—psoriasis	3.71e-05	0.000215	CcSEcCtD
Sunitinib—Urethral disorder—Methotrexate—psoriasis	3.7e-05	0.000213	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Triamcinolone—psoriasis	3.7e-05	0.000213	CcSEcCtD
Sunitinib—Pain—Hydrocortisone—psoriasis	3.68e-05	0.000213	CcSEcCtD
Sunitinib—Oedema—Dexamethasone—psoriasis	3.68e-05	0.000213	CcSEcCtD
Sunitinib—Oedema—Betamethasone—psoriasis	3.68e-05	0.000213	CcSEcCtD
Sunitinib—Insomnia—Triamcinolone—psoriasis	3.67e-05	0.000212	CcSEcCtD
Sunitinib—Infection—Betamethasone—psoriasis	3.66e-05	0.000211	CcSEcCtD
Sunitinib—Infection—Dexamethasone—psoriasis	3.66e-05	0.000211	CcSEcCtD
Sunitinib—Paraesthesia—Triamcinolone—psoriasis	3.64e-05	0.00021	CcSEcCtD
Sunitinib—Anaemia—Prednisone—psoriasis	3.63e-05	0.00021	CcSEcCtD
Sunitinib—Shock—Dexamethasone—psoriasis	3.62e-05	0.000209	CcSEcCtD
Sunitinib—Shock—Betamethasone—psoriasis	3.62e-05	0.000209	CcSEcCtD
Sunitinib—Dyspnoea—Triamcinolone—psoriasis	3.62e-05	0.000209	CcSEcCtD
Sunitinib—Nervous system disorder—Dexamethasone—psoriasis	3.61e-05	0.000208	CcSEcCtD
Sunitinib—Nervous system disorder—Betamethasone—psoriasis	3.61e-05	0.000208	CcSEcCtD
Sunitinib—Thrombocytopenia—Dexamethasone—psoriasis	3.6e-05	0.000208	CcSEcCtD
Sunitinib—Thrombocytopenia—Betamethasone—psoriasis	3.6e-05	0.000208	CcSEcCtD
Sunitinib—Angioedema—Prednisone—psoriasis	3.59e-05	0.000207	CcSEcCtD
Sunitinib—Hypersensitivity—Cyclosporine—psoriasis	3.57e-05	0.000206	CcSEcCtD
Sunitinib—Dyspepsia—Triamcinolone—psoriasis	3.57e-05	0.000206	CcSEcCtD
Sunitinib—Erythema multiforme—Methotrexate—psoriasis	3.57e-05	0.000206	CcSEcCtD
Sunitinib—Nausea—Mycophenolic acid—psoriasis	3.56e-05	0.000206	CcSEcCtD
Sunitinib—Eye disorder—Methotrexate—psoriasis	3.52e-05	0.000204	CcSEcCtD
Sunitinib—Gastrointestinal pain—Hydrocortisone—psoriasis	3.52e-05	0.000203	CcSEcCtD
Sunitinib—Anorexia—Dexamethasone—psoriasis	3.51e-05	0.000203	CcSEcCtD
Sunitinib—Anorexia—Betamethasone—psoriasis	3.51e-05	0.000203	CcSEcCtD
Sunitinib—Cardiac disorder—Methotrexate—psoriasis	3.5e-05	0.000202	CcSEcCtD
Sunitinib—Fatigue—Triamcinolone—psoriasis	3.5e-05	0.000202	CcSEcCtD
Sunitinib—Hypersensitivity—Mycophenolate mofetil—psoriasis	3.48e-05	0.000201	CcSEcCtD
Sunitinib—Asthenia—Cyclosporine—psoriasis	3.48e-05	0.000201	CcSEcCtD
Sunitinib—Pain—Triamcinolone—psoriasis	3.47e-05	0.0002	CcSEcCtD
Sunitinib—Pruritus—Cyclosporine—psoriasis	3.43e-05	0.000198	CcSEcCtD
Sunitinib—Angiopathy—Methotrexate—psoriasis	3.42e-05	0.000198	CcSEcCtD
Sunitinib—Immune system disorder—Methotrexate—psoriasis	3.41e-05	0.000197	CcSEcCtD
Sunitinib—Body temperature increased—Hydrocortisone—psoriasis	3.41e-05	0.000197	CcSEcCtD
Sunitinib—Abdominal pain—Hydrocortisone—psoriasis	3.41e-05	0.000197	CcSEcCtD
Sunitinib—Convulsion—Prednisone—psoriasis	3.4e-05	0.000197	CcSEcCtD
Sunitinib—Mediastinal disorder—Methotrexate—psoriasis	3.4e-05	0.000196	CcSEcCtD
Sunitinib—Asthenia—Mycophenolate mofetil—psoriasis	3.39e-05	0.000196	CcSEcCtD
Sunitinib—Hypertension—Prednisone—psoriasis	3.39e-05	0.000196	CcSEcCtD
Sunitinib—Chills—Methotrexate—psoriasis	3.38e-05	0.000195	CcSEcCtD
Sunitinib—PRPF4—Norethindrone—Hydrocortisone—psoriasis	3.36e-05	0.00955	CbGdCrCtD
Sunitinib—Musculoskeletal discomfort—Betamethasone—psoriasis	3.35e-05	0.000194	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Dexamethasone—psoriasis	3.35e-05	0.000194	CcSEcCtD
Sunitinib—Pruritus—Mycophenolate mofetil—psoriasis	3.35e-05	0.000193	CcSEcCtD
Sunitinib—Arthralgia—Prednisone—psoriasis	3.34e-05	0.000193	CcSEcCtD
Sunitinib—Myalgia—Prednisone—psoriasis	3.34e-05	0.000193	CcSEcCtD
Sunitinib—Alopecia—Methotrexate—psoriasis	3.33e-05	0.000192	CcSEcCtD
Sunitinib—Insomnia—Dexamethasone—psoriasis	3.33e-05	0.000192	CcSEcCtD
Sunitinib—Insomnia—Betamethasone—psoriasis	3.33e-05	0.000192	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	3.32e-05	0.000192	CcSEcCtD
Sunitinib—Diarrhoea—Cyclosporine—psoriasis	3.32e-05	0.000192	CcSEcCtD
Sunitinib—Paraesthesia—Dexamethasone—psoriasis	3.31e-05	0.000191	CcSEcCtD
Sunitinib—Paraesthesia—Betamethasone—psoriasis	3.31e-05	0.000191	CcSEcCtD
Sunitinib—Mental disorder—Methotrexate—psoriasis	3.3e-05	0.000191	CcSEcCtD
Sunitinib—Malnutrition—Methotrexate—psoriasis	3.28e-05	0.00019	CcSEcCtD
Sunitinib—Erythema—Methotrexate—psoriasis	3.28e-05	0.00019	CcSEcCtD
Sunitinib—Hypersensitivity—Prednisolone—psoriasis	3.25e-05	0.000188	CcSEcCtD
Sunitinib—CSNK1E—Betamethasone—Hydrocortisone—psoriasis	3.24e-05	0.00922	CbGdCrCtD
Sunitinib—CSNK1E—Dexamethasone—Hydrocortisone—psoriasis	3.24e-05	0.00922	CbGdCrCtD
Sunitinib—Dyspepsia—Betamethasone—psoriasis	3.24e-05	0.000187	CcSEcCtD
Sunitinib—Dyspepsia—Dexamethasone—psoriasis	3.24e-05	0.000187	CcSEcCtD
Sunitinib—Diarrhoea—Mycophenolate mofetil—psoriasis	3.24e-05	0.000187	CcSEcCtD
Sunitinib—Dysgeusia—Methotrexate—psoriasis	3.21e-05	0.000186	CcSEcCtD
Sunitinib—Body temperature increased—Triamcinolone—psoriasis	3.21e-05	0.000185	CcSEcCtD
Sunitinib—Dizziness—Cyclosporine—psoriasis	3.21e-05	0.000185	CcSEcCtD
Sunitinib—Oedema—Prednisone—psoriasis	3.21e-05	0.000185	CcSEcCtD
Sunitinib—Decreased appetite—Dexamethasone—psoriasis	3.2e-05	0.000185	CcSEcCtD
Sunitinib—Decreased appetite—Betamethasone—psoriasis	3.2e-05	0.000185	CcSEcCtD
Sunitinib—Infection—Prednisone—psoriasis	3.18e-05	0.000184	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Dexamethasone—psoriasis	3.18e-05	0.000184	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Betamethasone—psoriasis	3.18e-05	0.000184	CcSEcCtD
Sunitinib—Back pain—Methotrexate—psoriasis	3.18e-05	0.000183	CcSEcCtD
Sunitinib—Hypersensitivity—Hydrocortisone—psoriasis	3.17e-05	0.000183	CcSEcCtD
Sunitinib—Fatigue—Dexamethasone—psoriasis	3.17e-05	0.000183	CcSEcCtD
Sunitinib—Fatigue—Betamethasone—psoriasis	3.17e-05	0.000183	CcSEcCtD
Sunitinib—Shock—Prednisone—psoriasis	3.15e-05	0.000182	CcSEcCtD
Sunitinib—Pain—Dexamethasone—psoriasis	3.15e-05	0.000182	CcSEcCtD
Sunitinib—Pain—Betamethasone—psoriasis	3.15e-05	0.000182	CcSEcCtD
Sunitinib—Nervous system disorder—Prednisone—psoriasis	3.14e-05	0.000182	CcSEcCtD
Sunitinib—CHEK2—Testosterone Propionate—Hydrocortisone—psoriasis	3.13e-05	0.00889	CbGdCrCtD
Sunitinib—Dizziness—Mycophenolate mofetil—psoriasis	3.13e-05	0.000181	CcSEcCtD
Sunitinib—Skin disorder—Prednisone—psoriasis	3.11e-05	0.00018	CcSEcCtD
Sunitinib—Asthenia—Hydrocortisone—psoriasis	3.09e-05	0.000179	CcSEcCtD
Sunitinib—Vomiting—Cyclosporine—psoriasis	3.08e-05	0.000178	CcSEcCtD
Sunitinib—Rash—Cyclosporine—psoriasis	3.06e-05	0.000177	CcSEcCtD
Sunitinib—Anorexia—Prednisone—psoriasis	3.06e-05	0.000176	CcSEcCtD
Sunitinib—Dermatitis—Cyclosporine—psoriasis	3.05e-05	0.000176	CcSEcCtD
Sunitinib—Pruritus—Hydrocortisone—psoriasis	3.05e-05	0.000176	CcSEcCtD
Sunitinib—Headache—Cyclosporine—psoriasis	3.04e-05	0.000175	CcSEcCtD
Sunitinib—Anaemia—Methotrexate—psoriasis	3.03e-05	0.000175	CcSEcCtD
Sunitinib—CSNK1E—Dexamethasone—Betamethasone—psoriasis	3.01e-05	0.00856	CbGdCrCtD
Sunitinib—CSNK1E—Betamethasone—Dexamethasone—psoriasis	3.01e-05	0.00856	CbGdCrCtD
Sunitinib—Gastrointestinal pain—Betamethasone—psoriasis	3.01e-05	0.000174	CcSEcCtD
Sunitinib—Gastrointestinal pain—Dexamethasone—psoriasis	3.01e-05	0.000174	CcSEcCtD
Sunitinib—Vomiting—Mycophenolate mofetil—psoriasis	3.01e-05	0.000174	CcSEcCtD
Sunitinib—Hypersensitivity—Triamcinolone—psoriasis	2.99e-05	0.000173	CcSEcCtD
Sunitinib—Rash—Mycophenolate mofetil—psoriasis	2.98e-05	0.000172	CcSEcCtD
Sunitinib—Dermatitis—Mycophenolate mofetil—psoriasis	2.98e-05	0.000172	CcSEcCtD
Sunitinib—Headache—Mycophenolate mofetil—psoriasis	2.96e-05	0.000171	CcSEcCtD
Sunitinib—Diarrhoea—Hydrocortisone—psoriasis	2.95e-05	0.00017	CcSEcCtD
Sunitinib—CSNK1E—Betamethasone—Triamcinolone—psoriasis	2.94e-05	0.00837	CbGdCrCtD
Sunitinib—CSNK1E—Dexamethasone—Triamcinolone—psoriasis	2.94e-05	0.00837	CbGdCrCtD
Sunitinib—Leukopenia—Methotrexate—psoriasis	2.94e-05	0.00017	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Prednisone—psoriasis	2.92e-05	0.000169	CcSEcCtD
Sunitinib—Dizziness—Prednisolone—psoriasis	2.92e-05	0.000168	CcSEcCtD
Sunitinib—Asthenia—Triamcinolone—psoriasis	2.91e-05	0.000168	CcSEcCtD
Sunitinib—Body temperature increased—Betamethasone—psoriasis	2.91e-05	0.000168	CcSEcCtD
Sunitinib—Body temperature increased—Dexamethasone—psoriasis	2.91e-05	0.000168	CcSEcCtD
Sunitinib—Abdominal pain—Dexamethasone—psoriasis	2.91e-05	0.000168	CcSEcCtD
Sunitinib—Abdominal pain—Betamethasone—psoriasis	2.91e-05	0.000168	CcSEcCtD
Sunitinib—Insomnia—Prednisone—psoriasis	2.9e-05	0.000167	CcSEcCtD
Sunitinib—Nausea—Cyclosporine—psoriasis	2.88e-05	0.000166	CcSEcCtD
Sunitinib—Paraesthesia—Prednisone—psoriasis	2.88e-05	0.000166	CcSEcCtD
Sunitinib—Pruritus—Triamcinolone—psoriasis	2.87e-05	0.000166	CcSEcCtD
Sunitinib—Cough—Methotrexate—psoriasis	2.86e-05	0.000165	CcSEcCtD
Sunitinib—Dizziness—Hydrocortisone—psoriasis	2.85e-05	0.000165	CcSEcCtD
Sunitinib—Convulsion—Methotrexate—psoriasis	2.84e-05	0.000164	CcSEcCtD
Sunitinib—Dyspepsia—Prednisone—psoriasis	2.82e-05	0.000163	CcSEcCtD
Sunitinib—Nausea—Mycophenolate mofetil—psoriasis	2.81e-05	0.000162	CcSEcCtD
Sunitinib—Chest pain—Methotrexate—psoriasis	2.79e-05	0.000161	CcSEcCtD
Sunitinib—Myalgia—Methotrexate—psoriasis	2.79e-05	0.000161	CcSEcCtD
Sunitinib—Arthralgia—Methotrexate—psoriasis	2.79e-05	0.000161	CcSEcCtD
Sunitinib—CSNK1E—Dexamethasone—Prednisone—psoriasis	2.79e-05	0.00794	CbGdCrCtD
Sunitinib—CSNK1E—Betamethasone—Prednisone—psoriasis	2.79e-05	0.00794	CbGdCrCtD
Sunitinib—Decreased appetite—Prednisone—psoriasis	2.79e-05	0.000161	CcSEcCtD
Sunitinib—Rash—Prednisolone—psoriasis	2.78e-05	0.000161	CcSEcCtD
Sunitinib—Dermatitis—Prednisolone—psoriasis	2.78e-05	0.00016	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	2.78e-05	0.00016	CcSEcCtD
Sunitinib—Fatigue—Prednisone—psoriasis	2.76e-05	0.00016	CcSEcCtD
Sunitinib—Headache—Prednisolone—psoriasis	2.76e-05	0.00016	CcSEcCtD
Sunitinib—Constipation—Prednisone—psoriasis	2.74e-05	0.000158	CcSEcCtD
Sunitinib—Vomiting—Hydrocortisone—psoriasis	2.74e-05	0.000158	CcSEcCtD
Sunitinib—CSNK1E—Betamethasone—Prednisolone—psoriasis	2.73e-05	0.00775	CbGdCrCtD
Sunitinib—CSNK1E—Dexamethasone—Prednisolone—psoriasis	2.73e-05	0.00775	CbGdCrCtD
Sunitinib—Rash—Hydrocortisone—psoriasis	2.72e-05	0.000157	CcSEcCtD
Sunitinib—Dermatitis—Hydrocortisone—psoriasis	2.71e-05	0.000157	CcSEcCtD
Sunitinib—Headache—Hydrocortisone—psoriasis	2.7e-05	0.000156	CcSEcCtD
Sunitinib—Dizziness—Triamcinolone—psoriasis	2.68e-05	0.000155	CcSEcCtD
Sunitinib—PRPF4—Levonorgestrel—Hydrocortisone—psoriasis	2.67e-05	0.0076	CbGdCrCtD
Sunitinib—Infection—Methotrexate—psoriasis	2.66e-05	0.000154	CcSEcCtD
Sunitinib—Asthenia—Betamethasone—psoriasis	2.64e-05	0.000153	CcSEcCtD
Sunitinib—Asthenia—Dexamethasone—psoriasis	2.64e-05	0.000153	CcSEcCtD
Sunitinib—Nervous system disorder—Methotrexate—psoriasis	2.63e-05	0.000152	CcSEcCtD
Sunitinib—Thrombocytopenia—Methotrexate—psoriasis	2.62e-05	0.000151	CcSEcCtD
Sunitinib—Gastrointestinal pain—Prednisone—psoriasis	2.62e-05	0.000151	CcSEcCtD
Sunitinib—Nausea—Prednisolone—psoriasis	2.62e-05	0.000151	CcSEcCtD
Sunitinib—Pruritus—Betamethasone—psoriasis	2.6e-05	0.00015	CcSEcCtD
Sunitinib—Pruritus—Dexamethasone—psoriasis	2.6e-05	0.00015	CcSEcCtD
Sunitinib—Skin disorder—Methotrexate—psoriasis	2.6e-05	0.00015	CcSEcCtD
Sunitinib—CHEK2—Danazol—Hydrocortisone—psoriasis	2.6e-05	0.00739	CbGdCrCtD
Sunitinib—Vomiting—Triamcinolone—psoriasis	2.58e-05	0.000149	CcSEcCtD
Sunitinib—Nausea—Hydrocortisone—psoriasis	2.56e-05	0.000148	CcSEcCtD
Sunitinib—Rash—Triamcinolone—psoriasis	2.56e-05	0.000148	CcSEcCtD
Sunitinib—Dermatitis—Triamcinolone—psoriasis	2.56e-05	0.000148	CcSEcCtD
Sunitinib—Anorexia—Methotrexate—psoriasis	2.55e-05	0.000147	CcSEcCtD
Sunitinib—Headache—Triamcinolone—psoriasis	2.54e-05	0.000147	CcSEcCtD
Sunitinib—Abdominal pain—Prednisone—psoriasis	2.53e-05	0.000146	CcSEcCtD
Sunitinib—Body temperature increased—Prednisone—psoriasis	2.53e-05	0.000146	CcSEcCtD
Sunitinib—Diarrhoea—Betamethasone—psoriasis	2.52e-05	0.000145	CcSEcCtD
Sunitinib—Diarrhoea—Dexamethasone—psoriasis	2.52e-05	0.000145	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Methotrexate—psoriasis	2.44e-05	0.000141	CcSEcCtD
Sunitinib—Dizziness—Betamethasone—psoriasis	2.43e-05	0.000141	CcSEcCtD
Sunitinib—Dizziness—Dexamethasone—psoriasis	2.43e-05	0.000141	CcSEcCtD
Sunitinib—Insomnia—Methotrexate—psoriasis	2.42e-05	0.00014	CcSEcCtD
Sunitinib—Nausea—Triamcinolone—psoriasis	2.41e-05	0.000139	CcSEcCtD
Sunitinib—Paraesthesia—Methotrexate—psoriasis	2.41e-05	0.000139	CcSEcCtD
Sunitinib—Dyspnoea—Methotrexate—psoriasis	2.39e-05	0.000138	CcSEcCtD
Sunitinib—Hypersensitivity—Prednisone—psoriasis	2.36e-05	0.000136	CcSEcCtD
Sunitinib—Dyspepsia—Methotrexate—psoriasis	2.36e-05	0.000136	CcSEcCtD
Sunitinib—CHEK2—Norethindrone—Hydrocortisone—psoriasis	2.34e-05	0.00666	CbGdCrCtD
Sunitinib—Vomiting—Dexamethasone—psoriasis	2.34e-05	0.000135	CcSEcCtD
Sunitinib—Vomiting—Betamethasone—psoriasis	2.34e-05	0.000135	CcSEcCtD
Sunitinib—Decreased appetite—Methotrexate—psoriasis	2.33e-05	0.000134	CcSEcCtD
Sunitinib—Rash—Betamethasone—psoriasis	2.32e-05	0.000134	CcSEcCtD
Sunitinib—Rash—Dexamethasone—psoriasis	2.32e-05	0.000134	CcSEcCtD
Sunitinib—Dermatitis—Dexamethasone—psoriasis	2.32e-05	0.000134	CcSEcCtD
Sunitinib—Dermatitis—Betamethasone—psoriasis	2.32e-05	0.000134	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Methotrexate—psoriasis	2.31e-05	0.000134	CcSEcCtD
Sunitinib—Fatigue—Methotrexate—psoriasis	2.31e-05	0.000133	CcSEcCtD
Sunitinib—Headache—Betamethasone—psoriasis	2.31e-05	0.000133	CcSEcCtD
Sunitinib—Headache—Dexamethasone—psoriasis	2.31e-05	0.000133	CcSEcCtD
Sunitinib—Asthenia—Prednisone—psoriasis	2.3e-05	0.000133	CcSEcCtD
Sunitinib—Pain—Methotrexate—psoriasis	2.29e-05	0.000132	CcSEcCtD
Sunitinib—Pruritus—Prednisone—psoriasis	2.27e-05	0.000131	CcSEcCtD
Sunitinib—CHEK2—Danazol—Prednisone—psoriasis	2.24e-05	0.00637	CbGdCrCtD
Sunitinib—Diarrhoea—Prednisone—psoriasis	2.19e-05	0.000127	CcSEcCtD
Sunitinib—Gastrointestinal pain—Methotrexate—psoriasis	2.19e-05	0.000127	CcSEcCtD
Sunitinib—Nausea—Dexamethasone—psoriasis	2.19e-05	0.000126	CcSEcCtD
Sunitinib—Nausea—Betamethasone—psoriasis	2.19e-05	0.000126	CcSEcCtD
Sunitinib—Dizziness—Prednisone—psoriasis	2.12e-05	0.000122	CcSEcCtD
Sunitinib—Abdominal pain—Methotrexate—psoriasis	2.12e-05	0.000122	CcSEcCtD
Sunitinib—Body temperature increased—Methotrexate—psoriasis	2.12e-05	0.000122	CcSEcCtD
Sunitinib—Vomiting—Prednisone—psoriasis	2.04e-05	0.000118	CcSEcCtD
Sunitinib—Rash—Prednisone—psoriasis	2.02e-05	0.000117	CcSEcCtD
Sunitinib—Dermatitis—Prednisone—psoriasis	2.02e-05	0.000117	CcSEcCtD
Sunitinib—Headache—Prednisone—psoriasis	2.01e-05	0.000116	CcSEcCtD
Sunitinib—Hypersensitivity—Methotrexate—psoriasis	1.97e-05	0.000114	CcSEcCtD
Sunitinib—Asthenia—Methotrexate—psoriasis	1.92e-05	0.000111	CcSEcCtD
Sunitinib—Nausea—Prednisone—psoriasis	1.9e-05	0.00011	CcSEcCtD
Sunitinib—Pruritus—Methotrexate—psoriasis	1.9e-05	0.000109	CcSEcCtD
Sunitinib—CHEK2—Levonorgestrel—Hydrocortisone—psoriasis	1.86e-05	0.0053	CbGdCrCtD
Sunitinib—Diarrhoea—Methotrexate—psoriasis	1.83e-05	0.000106	CcSEcCtD
Sunitinib—Dizziness—Methotrexate—psoriasis	1.77e-05	0.000102	CcSEcCtD
Sunitinib—Vomiting—Methotrexate—psoriasis	1.7e-05	9.84e-05	CcSEcCtD
Sunitinib—Rash—Methotrexate—psoriasis	1.69e-05	9.76e-05	CcSEcCtD
Sunitinib—Dermatitis—Methotrexate—psoriasis	1.69e-05	9.75e-05	CcSEcCtD
Sunitinib—Headache—Methotrexate—psoriasis	1.68e-05	9.69e-05	CcSEcCtD
Sunitinib—Nausea—Methotrexate—psoriasis	1.59e-05	9.19e-05	CcSEcCtD
Sunitinib—JAK2—Disease—TYK2—psoriasis	1.89e-06	1.14e-05	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—JUN—psoriasis	1.88e-06	1.13e-05	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—NFKB1—psoriasis	1.88e-06	1.13e-05	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—VEGFA—psoriasis	1.88e-06	1.13e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Innate Immune System—IL6—psoriasis	1.87e-06	1.13e-05	CbGpPWpGaD
Sunitinib—CSNK1A1—Signaling Pathways—TP53—psoriasis	1.87e-06	1.13e-05	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—JUN—psoriasis	1.87e-06	1.13e-05	CbGpPWpGaD
Sunitinib—FGFR2—Immune System—STAT3—psoriasis	1.86e-06	1.13e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—CD4—psoriasis	1.86e-06	1.12e-05	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—VEGFA—psoriasis	1.86e-06	1.12e-05	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—STAT3—psoriasis	1.86e-06	1.12e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—JUN—psoriasis	1.85e-06	1.12e-05	CbGpPWpGaD
Sunitinib—JAK2—Immune System—CD4—psoriasis	1.85e-06	1.12e-05	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—STAT3—psoriasis	1.84e-06	1.11e-05	CbGpPWpGaD
Sunitinib—KIT—Immune System—STAT3—psoriasis	1.83e-06	1.11e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—STAT3—psoriasis	1.83e-06	1.11e-05	CbGpPWpGaD
Sunitinib—PTK2B—Immune System—IL6—psoriasis	1.82e-06	1.1e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—LEP—psoriasis	1.82e-06	1.1e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—APOE—psoriasis	1.82e-06	1.1e-05	CbGpPWpGaD
Sunitinib—RPS6KA5—Signaling Pathways—IL6—psoriasis	1.82e-06	1.1e-05	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—JUN—psoriasis	1.81e-06	1.09e-05	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—JUN—psoriasis	1.81e-06	1.09e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—LEP—psoriasis	1.81e-06	1.09e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—APOE—psoriasis	1.81e-06	1.09e-05	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—NFKB1—psoriasis	1.81e-06	1.09e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—JUN—psoriasis	1.81e-06	1.09e-05	CbGpPWpGaD
Sunitinib—FYN—Innate Immune System—IL6—psoriasis	1.81e-06	1.09e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—NFKBIA—psoriasis	1.8e-06	1.09e-05	CbGpPWpGaD
Sunitinib—RPS6KA2—Signaling Pathways—IL6—psoriasis	1.8e-06	1.09e-05	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—NFKB1—psoriasis	1.8e-06	1.09e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—TYK2—psoriasis	1.8e-06	1.08e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Innate Immune System—IL6—psoriasis	1.8e-06	1.08e-05	CbGpPWpGaD
Sunitinib—FYN—Disease—CD4—psoriasis	1.79e-06	1.08e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—CD4—psoriasis	1.79e-06	1.08e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—NFKB1—psoriasis	1.78e-06	1.07e-05	CbGpPWpGaD
Sunitinib—BLK—Immune System—IL6—psoriasis	1.78e-06	1.07e-05	CbGpPWpGaD
Sunitinib—FGR—Immune System—IL6—psoriasis	1.77e-06	1.07e-05	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—JUN—psoriasis	1.77e-06	1.07e-05	CbGpPWpGaD
Sunitinib—RPS6KA1—Signaling Pathways—TP53—psoriasis	1.76e-06	1.07e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—NFKBIA—psoriasis	1.76e-06	1.06e-05	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—APOE—psoriasis	1.76e-06	1.06e-05	CbGpPWpGaD
Sunitinib—FLT1—Signaling Pathways—TP53—psoriasis	1.75e-06	1.06e-05	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—NFKB1—psoriasis	1.74e-06	1.05e-05	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—NFKB1—psoriasis	1.74e-06	1.05e-05	CbGpPWpGaD
Sunitinib—TYK2—Disease—STAT3—psoriasis	1.74e-06	1.05e-05	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—APOE—psoriasis	1.74e-06	1.05e-05	CbGpPWpGaD
Sunitinib—FYN—Immune System—JUN—psoriasis	1.74e-06	1.05e-05	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—STAT3—psoriasis	1.74e-06	1.05e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—NFKB1—psoriasis	1.74e-06	1.05e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—STAT3—psoriasis	1.73e-06	1.05e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—LEP—psoriasis	1.73e-06	1.04e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—APOE—psoriasis	1.73e-06	1.04e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—JUN—psoriasis	1.73e-06	1.04e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—TYK2—psoriasis	1.72e-06	1.04e-05	CbGpPWpGaD
Sunitinib—FGFR2—Disease—STAT3—psoriasis	1.72e-06	1.04e-05	CbGpPWpGaD
Sunitinib—JAK2—Innate Immune System—IL6—psoriasis	1.72e-06	1.04e-05	CbGpPWpGaD
Sunitinib—CSNK1A1—Signaling Pathways—IL6—psoriasis	1.71e-06	1.03e-05	CbGpPWpGaD
Sunitinib—JAK2—Disease—CD4—psoriasis	1.71e-06	1.03e-05	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—VEGFA—psoriasis	1.71e-06	1.03e-05	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—NFKB1—psoriasis	1.7e-06	1.03e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—NFKBIA—psoriasis	1.7e-06	1.02e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—TYK2—psoriasis	1.69e-06	1.02e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—TYK2—psoriasis	1.69e-06	1.02e-05	CbGpPWpGaD
Sunitinib—KIT—Disease—STAT3—psoriasis	1.69e-06	1.02e-05	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—STAT3—psoriasis	1.69e-06	1.02e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—NFKBIA—psoriasis	1.69e-06	1.02e-05	CbGpPWpGaD
Sunitinib—FYN—Immune System—NFKB1—psoriasis	1.68e-06	1.01e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—NFKB1—psoriasis	1.67e-06	1.01e-05	CbGpPWpGaD
Sunitinib—JAK2—Immune System—JUN—psoriasis	1.65e-06	9.98e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—CXCL8—psoriasis	1.65e-06	9.95e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—VEGFA—psoriasis	1.64e-06	9.91e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—VEGFA—psoriasis	1.63e-06	9.85e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—STAT3—psoriasis	1.63e-06	9.82e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—CAT—psoriasis	1.62e-06	9.78e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—STAT3—psoriasis	1.62e-06	9.75e-06	CbGpPWpGaD
Sunitinib—RPS6KA1—Signaling Pathways—IL6—psoriasis	1.62e-06	9.75e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—NFKBIA—psoriasis	1.61e-06	9.74e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—TYK2—psoriasis	1.6e-06	9.69e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—STAT3—psoriasis	1.6e-06	9.69e-06	CbGpPWpGaD
Sunitinib—FLT1—Signaling Pathways—IL6—psoriasis	1.6e-06	9.68e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—TYK2—psoriasis	1.6e-06	9.66e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—STAT3—psoriasis	1.6e-06	9.66e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—STAT3—psoriasis	1.6e-06	9.66e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—NFKB1—psoriasis	1.59e-06	9.61e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—VEGFA—psoriasis	1.58e-06	9.55e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—VEGFA—psoriasis	1.58e-06	9.55e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—STAT3—psoriasis	1.57e-06	9.46e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—STAT3—psoriasis	1.57e-06	9.46e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—CXCL8—psoriasis	1.56e-06	9.44e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—STAT3—psoriasis	1.56e-06	9.43e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—VEGFA—psoriasis	1.54e-06	9.31e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—JUN—psoriasis	1.53e-06	9.25e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—PPARG—psoriasis	1.53e-06	9.24e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—STAT3—psoriasis	1.53e-06	9.22e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—CXCL8—psoriasis	1.52e-06	9.16e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—PPARG—psoriasis	1.52e-06	9.15e-06	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—TP53—psoriasis	1.51e-06	9.13e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—STAT3—psoriasis	1.51e-06	9.09e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—CXCL8—psoriasis	1.5e-06	9.05e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—STAT3—psoriasis	1.5e-06	9.04e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—TYK2—psoriasis	1.48e-06	8.92e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—STAT3—psoriasis	1.48e-06	8.92e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—NFKB1—psoriasis	1.48e-06	8.9e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—CXCL8—psoriasis	1.47e-06	8.89e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—CXCL8—psoriasis	1.47e-06	8.89e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—JUN—psoriasis	1.45e-06	8.77e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling by GPCR—IL6—psoriasis	1.44e-06	8.71e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—TYK2—psoriasis	1.44e-06	8.7e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—STAT3—psoriasis	1.44e-06	8.7e-06	CbGpPWpGaD
Sunitinib—YES1—Immune System—IL6—psoriasis	1.43e-06	8.65e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—STAT3—psoriasis	1.43e-06	8.64e-06	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—TP53—psoriasis	1.42e-06	8.56e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—JUN—psoriasis	1.41e-06	8.52e-06	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—TP53—psoriasis	1.41e-06	8.49e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—NFKB1—psoriasis	1.4e-06	8.45e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—CXCL8—psoriasis	1.4e-06	8.43e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—CXCL8—psoriasis	1.39e-06	8.41e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—JUN—psoriasis	1.39e-06	8.41e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—TYK2—psoriasis	1.39e-06	8.39e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—STAT3—psoriasis	1.39e-06	8.39e-06	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—IL6—psoriasis	1.38e-06	8.36e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—TYK2—psoriasis	1.38e-06	8.34e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—STAT3—psoriasis	1.38e-06	8.34e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—JUN—psoriasis	1.37e-06	8.26e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—JUN—psoriasis	1.37e-06	8.26e-06	CbGpPWpGaD
Sunitinib—IRAK1—Immune System—IL6—psoriasis	1.36e-06	8.2e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—NFKB1—psoriasis	1.36e-06	8.2e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—NFKB1—psoriasis	1.34e-06	8.1e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—VEGFA—psoriasis	1.34e-06	8.08e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—STAT3—psoriasis	1.33e-06	8e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—TYK2—psoriasis	1.32e-06	7.97e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—STAT3—psoriasis	1.32e-06	7.97e-06	CbGpPWpGaD
Sunitinib—TYK2—Immune System—IL6—psoriasis	1.32e-06	7.96e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—NFKB1—psoriasis	1.32e-06	7.95e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—NFKB1—psoriasis	1.32e-06	7.95e-06	CbGpPWpGaD
Sunitinib—FGFR2—Immune System—IL6—psoriasis	1.3e-06	7.86e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—JUN—psoriasis	1.3e-06	7.84e-06	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—IL6—psoriasis	1.3e-06	7.84e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—JUN—psoriasis	1.3e-06	7.82e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—TP53—psoriasis	1.29e-06	7.78e-06	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—IL6—psoriasis	1.29e-06	7.77e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—CXCL8—psoriasis	1.29e-06	7.77e-06	CbGpPWpGaD
Sunitinib—KIT—Immune System—IL6—psoriasis	1.28e-06	7.72e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—IL6—psoriasis	1.28e-06	7.72e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—VEGFA—psoriasis	1.27e-06	7.67e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—APOE—psoriasis	1.26e-06	7.6e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—STAT3—psoriasis	1.26e-06	7.59e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—CXCL8—psoriasis	1.26e-06	7.58e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—NFKB1—psoriasis	1.25e-06	7.55e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—NFKB1—psoriasis	1.25e-06	7.53e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—TP53—psoriasis	1.24e-06	7.49e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—TP53—psoriasis	1.23e-06	7.44e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—VEGFA—psoriasis	1.23e-06	7.44e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CARM1—psoriasis	1.22e-06	7.39e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by GPCR—IL6—psoriasis	1.22e-06	7.38e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—CAT—psoriasis	1.22e-06	7.38e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—STAT3—psoriasis	1.22e-06	7.37e-06	CbGpPWpGaD
Sunitinib—TYK2—Disease—IL6—psoriasis	1.22e-06	7.35e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—VEGFA—psoriasis	1.22e-06	7.35e-06	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—IL6—psoriasis	1.21e-06	7.33e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—IL6—psoriasis	1.21e-06	7.31e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CXCL8—psoriasis	1.21e-06	7.3e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—STAT3—psoriasis	1.21e-06	7.28e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CXCL8—psoriasis	1.2e-06	7.27e-06	CbGpPWpGaD
Sunitinib—FGFR2—Disease—IL6—psoriasis	1.2e-06	7.26e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—JUN—psoriasis	1.2e-06	7.22e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—VEGFA—psoriasis	1.2e-06	7.22e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—VEGFA—psoriasis	1.2e-06	7.22e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—TP53—psoriasis	1.2e-06	7.22e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—TP53—psoriasis	1.2e-06	7.22e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—STAT3—psoriasis	1.18e-06	7.15e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—STAT3—psoriasis	1.18e-06	7.15e-06	CbGpPWpGaD
Sunitinib—KIT—Disease—IL6—psoriasis	1.18e-06	7.13e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—IL6—psoriasis	1.18e-06	7.12e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—JUN—psoriasis	1.17e-06	7.05e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—TP53—psoriasis	1.17e-06	7.03e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—NFKB1—psoriasis	1.15e-06	6.95e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CXCL8—psoriasis	1.15e-06	6.94e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—IL6—psoriasis	1.14e-06	6.91e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—IL6—psoriasis	1.14e-06	6.86e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—VEGFA—psoriasis	1.13e-06	6.85e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—VEGFA—psoriasis	1.13e-06	6.83e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—IL6—psoriasis	1.13e-06	6.81e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—JUN—psoriasis	1.13e-06	6.79e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—STAT3—psoriasis	1.12e-06	6.78e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—NFKB1—psoriasis	1.12e-06	6.78e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—IL6—psoriasis	1.12e-06	6.77e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—STAT3—psoriasis	1.12e-06	6.76e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—JUN—psoriasis	1.12e-06	6.75e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—IL6—psoriasis	1.12e-06	6.75e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—IL6—psoriasis	1.12e-06	6.75e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PPARG—psoriasis	1.1e-06	6.62e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—IL6—psoriasis	1.09e-06	6.61e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—IL6—psoriasis	1.09e-06	6.61e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—IL6—psoriasis	1.09e-06	6.6e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—IL6—psoriasis	1.09e-06	6.58e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—NFKB1—psoriasis	1.08e-06	6.54e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—NFKB1—psoriasis	1.08e-06	6.5e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—JUN—psoriasis	1.07e-06	6.46e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—IL6—psoriasis	1.07e-06	6.44e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—IL6—psoriasis	1.05e-06	6.35e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—IL6—psoriasis	1.05e-06	6.31e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—VEGFA—psoriasis	1.04e-06	6.31e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—STAT3—psoriasis	1.03e-06	6.25e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—IL6—psoriasis	1.03e-06	6.23e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—NFKB1—psoriasis	1.03e-06	6.21e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—VEGFA—psoriasis	1.02e-06	6.16e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—TP53—psoriasis	1.01e-06	6.11e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—STAT3—psoriasis	1.01e-06	6.09e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—IL6—psoriasis	1.01e-06	6.08e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—IL6—psoriasis	9.99e-07	6.03e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—VEGFA—psoriasis	9.83e-07	5.93e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—VEGFA—psoriasis	9.78e-07	5.9e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—STAT3—psoriasis	9.73e-07	5.87e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—IL6—psoriasis	9.71e-07	5.86e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—STAT3—psoriasis	9.68e-07	5.84e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—IL6—psoriasis	9.66e-07	5.83e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—TP53—psoriasis	9.6e-07	5.79e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—APOE—psoriasis	9.5e-07	5.73e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—VEGFA—psoriasis	9.34e-07	5.64e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—TP53—psoriasis	9.31e-07	5.62e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—IL6—psoriasis	9.26e-07	5.59e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—STAT3—psoriasis	9.25e-07	5.58e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—IL6—psoriasis	9.23e-07	5.57e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—TP53—psoriasis	9.2e-07	5.55e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—TP53—psoriasis	9.03e-07	5.45e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—TP53—psoriasis	9.03e-07	5.45e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—IL6—psoriasis	8.78e-07	5.3e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—TP53—psoriasis	8.57e-07	5.18e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—TP53—psoriasis	8.55e-07	5.16e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—IL6—psoriasis	8.53e-07	5.15e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—IL6—psoriasis	8.42e-07	5.08e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PPARG—psoriasis	8.27e-07	4.99e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—IL6—psoriasis	8.27e-07	4.99e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—IL6—psoriasis	8.27e-07	4.99e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—TP53—psoriasis	7.9e-07	4.77e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—IL6—psoriasis	7.85e-07	4.74e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—IL6—psoriasis	7.83e-07	4.73e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—TP53—psoriasis	7.7e-07	4.65e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CAT—psoriasis	7.53e-07	4.55e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—TP53—psoriasis	7.43e-07	4.48e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—TP53—psoriasis	7.39e-07	4.46e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—IL6—psoriasis	7.23e-07	4.36e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—TP53—psoriasis	7.06e-07	4.26e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—IL6—psoriasis	7.05e-07	4.26e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—IL6—psoriasis	6.8e-07	4.1e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—IL6—psoriasis	6.76e-07	4.08e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—IL6—psoriasis	6.46e-07	3.9e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—APOE—psoriasis	5.85e-07	3.53e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PPARG—psoriasis	5.1e-07	3.08e-06	CbGpPWpGaD
